Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats

被引:0
|
作者
Chu, XY [1 ]
Kato, Y [1 ]
Sugiyama, Y [1 ]
机构
[1] UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-II and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-II and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.
引用
收藏
页码:1934 / 1938
页数:5
相关论文
共 50 条
  • [1] Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
    Chu, XY
    Kato, Y
    Ueda, K
    Suzuki, H
    Niinuma, K
    Tyson, CA
    Weizer, V
    Dabbs, JE
    Froehlich, R
    Green, CE
    Sugiyama, Y
    CANCER RESEARCH, 1998, 58 (22) : 5137 - 5143
  • [2] Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver
    Tobin, PJ
    Hong, Y
    Seale, JP
    Rivory, LP
    McLachlan, AJ
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (01) : 39 - 45
  • [3] Irinotecan (CPT-11) metabolites in human bile and urine
    Lokiec, F
    duSorbier, BM
    Sanderink, GJ
    CLINICAL CANCER RESEARCH, 1996, 2 (12) : 1943 - 1949
  • [4] Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
    Chu, XY
    Kato, Y
    Sugiyama, Y
    DRUG METABOLISM AND DISPOSITION, 1999, 27 (04) : 440 - 441
  • [5] Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein
    Sugiyama, Y
    Kato, Y
    Chu, XY
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (Suppl 1) : S44 - S49
  • [6] Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein
    Yuichi Sugiyama
    Yukio Kato
    Xiao-yan Chu
    Cancer Chemotherapy and Pharmacology, 1998, 42 : S44 - S49
  • [7] In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab
    Ettlinger, DE
    Mitterhauser, M
    Wadsak, W
    Ostermann, E
    Farkouh, A
    Schueller, J
    Czejka, M
    ANTICANCER RESEARCH, 2006, 26 (2B) : 1337 - 1341
  • [8] Relationship between the initial uptake rate and cytotoxicity of irinotecan (CPT-11) and its metabolites.
    Ikegami, T
    Ha, L
    Ceryak, S
    Kobayashi, K
    Matsuzaki, Y
    Bouscarel, B
    GASTROENTEROLOGY, 2000, 118 (04) : A519 - A519
  • [9] Biliary excretion of irinotecan and its metabolites.
    Itoh, T
    Takemoto, I
    Itagaki, S
    Sasaki, K
    Hirano, T
    Iseki, K
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2004, 7 (01): : 13 - 18
  • [10] Irinotecan (CPT-11) for multiple myeloma
    Yano, H.
    Iida, S.
    Kayukawa, S.
    Nakagawa, C.
    Oguri, T.
    Ri, M.
    Inagaki, A.
    Sanda, T.
    Kusumoto, S.
    Ishida, T.
    Komatsu, H.
    Suzuki, A.
    Ueda, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 140 - 140